Sino Biopharmaceutical Reports Breakthrough in GVHD Treatment with Rovadicitinib

The latest announcement is out from Sino Biopharmaceutical ( (HK:1177) ).

Sino Biopharmaceutical Limited announced promising results from preclinical and Phase Ib clinical studies of rovadicitinib, a novel treatment for acute graft-versus-host disease (aGVHD), presented at the 2025 European Hematology Association Congress. The drug, a dual JAK/ROCK pathway inhibitor, showed an overall response rate of 84.6% at 28 days and a 12-month survival rate of 92.3%. These findings suggest rovadicitinib as a potential alternative for patients with steroid-refractory aGVHD, highlighting its rapid and sustained response and the ability to reduce steroid use. The company has also initiated a Phase III trial for chronic GVHD, reinforcing its commitment to advancing treatment options in this field.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited operates in the pharmaceutical industry, focusing on the development and production of a wide range of biopharmaceutical products. The company is particularly involved in innovative drug research and development, with a market focus on providing advanced treatment options for various diseases.

Average Trading Volume: 129,867,990

Technical Sentiment Signal: Buy

Current Market Cap: HK$94.43B

Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.